Jon Congleton - 13 Apr 2026 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role: Chief Executive Officer, Director
Signature: /s/ Adam Levy, Attorney-in-fact
Issuer symbol: MLYS
Transactions as of: 13 Apr 2026
Net transactions value: -$421,979
Form type: 4
Filing time: 15 Apr 2026, 21:45:20 UTC
Previous filing: 02 Apr 2026
Next filing: 29 Apr 2026
SEC: View on sec.gov

Key filing fact

Jon Congleton filed Form 4 for Mineralys Therapeutics, Inc. (MLYS) on 15 Apr 2026.

Key facts

This page summarizes Jon Congleton's Form 4 filing for Mineralys Therapeutics, Inc. (MLYS).
1 reported transaction and 0 derivative rows are listed below.
Filing timestamp: 15 Apr 2026, 21:45.

Change

Previous filing in this sequence was filed on 02 Apr 2026.
Current net transaction value: -$421,979.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

CIK 0001644975 Primary reporting owner

Congleton Jon

Relationship: Chief Executive Officer, Director
Address: 150 N. RADNOR CHESTER RD., SUITE F200, RADNOR
Signature: /s/ Adam Levy, Attorney-in-fact
Signature date: 15 Apr 2026

Transactions Table

MLYS transaction

Common Stock

Sale

Transaction value: $421,979
Shares: -15,730
Change %: -2.2%
Price: $26.83
Shares after: 689,321
Date: 13 Apr 2026
Ownership: Direct
Footnotes: F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025.
F2	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.81 to $26.96. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

Content

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025.

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.81 to $26.96. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.